會員登入
註冊
GlobalBio & Investment
Go Global and Beyond:
A Premier Biomedical Media in Taiwan
A Premier Biomedical Media in Taiwan
Lukas Biomedical has signed a strategic cooperation agreement with Korea's GC Cell
2024-07-22 / GlobalBio & Investment
GoodnewsofcelltherapiesinTaiwan!Today,LukasBiomedical(#路迦生醫)fromTaiwan,hassignedastrategiccooperationagreementwithKorea'sGCCelltodevelopandexpandthemarketforimmunecelltherapies.https://lnkd.in/gyd...
Forum addressing "How to become an interdisciplinary biomedical talent"
2024-07-19 / GlobalBio & Investment
Thisafternoon,TiBIA(TaiwanBiomedicalInnovationAssociation)andGlobalBio&InvestmentMonthlyheldaforumaddressing"howtobecomeaninterdisciplinarybiomedicaltalent",andinvitedthreerepresentative...
Join Us at the BIO Asia-Taiwan 2024!
2024-07-19 / GlobalBio & Investment
JoinUsattheBIOAsia-Taiwan2024!KickingoffnextWednesday,July24th,2024,theBIOAsia–TaiwanInternationalConferenceandExhibitionisbackforitssixthyear,bringingtogetherbiotechleadersfromTaiwan,theUS,Japa...
The seminar about organoids and organ-on-chips on new drug development
2024-07-18 / GlobalBio & Investment
Lastweek,wehadthehonortoholdaseminarwithNationalBiotechnologyResearchPark,BiomedicalTranslationResearchCenter,andMolecularDevices,toexplorethepotentials,futuretrendsandrevolutionoforganoidsandorgan-on...
Medical Taiwan 2024 Wraps Up with Record-Breaking Attendance
2024-07-17 / GlobalBio & Investment
MedicalTaiwan2024WrapsUpwithRecord-BreakingAttendance!MedicalTaiwan2024wrappeduponJune21,attractingover8,000visitors,a10%increasefromlastyear,withnearly1,000internationalattendeesfromJapan,Thailand,Ko...
List of 11 biopharma companies making headway to global markets
2024-07-16 / GlobalBio & Investment
During2024H1,biopharmacompaniesinTaiwanreceivedalotofgoodnewsinclinical,developmental,approvalandlicensingprogress.Inthisarticle,wesummarizedalistof11biopharmacompaniesmakingheadwaytoglobalmarkets.Let...
Biotech leaders from Taiwan, the US, Japan, and beyond to explore global business opportunities!
2024-07-16 / GlobalBio & Investment
KickingoffnextWednesday,July24th,2024,theBIOAsia-TaiwanInternationalConferenceandExhibitionisbackforitssixthyear,bringingtogetherbiotechleadersfromTaiwan,theUS,Japan,andbeyondtoexploreglobalbusinessop...
Medical Taiwan Visitors Grow 10% Year-on-year; Japan, Korea, and SE Asia Actively Participate
2024-07-16 / GlobalBio & Investment
MedicalTaiwan2024,athree-dayexhibition,wrappeduponJune21.Thisyear’sexhibitionissaidtobethelargestinitshistory,attractingover8,000visitorsoverthethree-dayexhibition,a10%increasefrom2023,andwithne...
圖爾思成立儀器部門以因應市場需求
2024-07-16 / GlobalBio & Investment
圖爾思生物科技股份有限公司儀器部門，致力於提供先進的生命科學儀器和設備，以支持各種生物科技研究和臨床應用。秉持著成為生技產業最佳合作夥伴與上游供應商，我們專注於引進和代理世界領先的科學儀器，目前代理了BeckmanCoulter、Cytiva、Leica等各大品牌，並提供全面的技術支持與服務，幫助科研人員實現高效、精確的實驗結果本次參展四大主題：從研究到生產，助力微生物產業的高效轉型加速生物製藥開...
新穎生醫啟動技術授權 爭取DNlite-IVD103納入預防指引
2024-07-16 / GlobalBio & Investment
新穎生醫DNlite-IVD103，是全球第一個應用於精準管理與預防糖尿病腎病變(DKD)腎功能快速惡化的檢測試劑，透過檢測尿液中特定生物標記的變化，可有效預測與監控患者未來5年腎功能的惡化狀況，達到疾病的精準照護與管理。DNlite-IVD103已取得歐盟多國、臺灣、馬來西亞、泰國、越南、印尼、沙烏地阿拉伯、阿拉伯聯合大公國等批准上市，適應症包括糖尿病腎病變(DKD)檢測、以及腎移植監控等，今年...
百奧賽圖與麥德凱生科攜手亮相BIO Asia-Taiwan
2024-07-16 / GlobalBio & Investment
百奧賽圖與麥德凱生科攜手參展亞洲頂級生技盛會，展位M1027生技服務區。MDG麥德凱生科為專業生技服務CRO，具GLP、ISO17025認證及國際級動物實驗中心，憑藉其豐富經驗和資源，與百奧賽圖聯合展出，共同推動臺灣新藥研發，帶來產業重大突破。百奧賽圖：全球新藥發源地的基因編輯領導者作為一家創新技術驅動的新藥研發國際性生物技術公司，百奧賽圖致力於成為全球新藥發源地。基於先進的基因編輯技術，自主研發...
基米續攻科研服務、臨床檢測、核酸/胜肽CDMO
2024-07-16 / GlobalBio & Investment
今(2024)年，國內基因定序領導大廠基龍米克斯(4195，簡稱基米)，宣布持續深化科研服務、臨床檢測、核酸/胜肽委託開發製造服務(CDMO)等三大核心業務布局，結合去年成立的新藥開發子公司萊斯特生醫，與合作夥伴資源多元化發展。今年以來，基米進行GMP核酸合成廠的產線優化，導入胜肽及短鏈核酸藥物的核心生產設備、分析儀器與專業團隊，不僅擴增佐劑產品組合，更領先同業跨足全方位的委託開發暨製造服務(CD...
